Cancer selective metallocenedicarboxylates of the fungal cytotoxin illudin M

Journal of Medicinal Chemistry

Volumn 54, Issue 18, 2011, Pages 6177-6182

  Schobert, Rainer ^a   Seibt, Sebastian ^a   Mahal, Katharina ^a   Ahmad, Aamir ^b   Biersack, Bernhard ^a   Effenberger Neidnicht, Katharina ^a   Padhye, Subhash ^b,c   Sarkar, Fazlul H ^b   Mueller, Thomas ^d  

^a UNIVERSITY OF BAYREUTH   (Germany)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PUNE   (India)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' FERROCENEDICARBOXYLIC ACID; ANTINEOPLASTIC AGENT; BIS(ILLUDIN M LACTONE) 1,1' RUTHENOCENEDICARBOXYLATE; BIS(ILLUDINYL M) 1,1' RUTHENOCENEDICARBOXYLATE; CARBOXYLIC ACID DERIVATIVE; ILLUDIN M; ILLUDIN M LACTONE 5; MITOGEN ACTIVATED PROTEIN KINASE; RUTHENOCENE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL STRAIN HCT116; CELL STRAIN HL 60; CELL STRAIN MCF 7; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG MEGADOSE; DRUG STABILITY; DRUG TOLERANCE; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN FIBROBLAST;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; COORDINATION COMPLEXES; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ESTERS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FUNGI; HUMANS; IRON; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LACTONES; MICE; MICE, NUDE; RUTHENIUM; SESQUITERPENES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80052815485     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200359n     Document Type: Article

References (26)

1. Anchel, M.; Hervey, A.; Robbins, W. J. Antibiotic substances from Basidiomycetes. VII. Clitocybe illudens Proc. Natl. Acad. Sci. U.S.A. 1950, 36, 300-305
2. McMorris, T. C.; Anchel, M. The structures of the basidiomycete metabolites illudin S and illudin M J. Am. Chem. Soc. 1963, 85, 831-832
3. McMorris, T. C.; Yu, J.; Lira, R.; Dawe, R.; MacDonald, J. R.; Waters, S. J.; Estes, L. A.; Kelner, M. J. Structure-activity studies of antitumor agent irofulven (hydroxymethylacylfulvene) and analogues J. Org. Chem. 2001, 66, 6158-6163 (Pubitemid 32847686)
4. Kelner, M. J.; McMorris, T. C.; Beck, W. T.; Zamora, J. M.; Taetle, R. Preclinical evaluation of illudins as anticancer agents Cancer Res. 1987, 47, 3186-3189 (Pubitemid 17082646)
5. Escargueil, A. E.; Poindessous, V.; Soares, D. G.; Sarasin, A.; Cook, P. R.; Larsen, A. K. Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cell J. Cell Sci. 2008, 8, 1275-1283 (Pubitemid 351753511)
6. Jaspers, N. G. J.; Raams, A.; Kelner, M. J.; Ng, J. M. Y.; Yamashita, Y. M.; Takeda, S.; McMorris, T. C.; Hoeijmakers, J. H. J. Antitumor compounds illudin S and irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways DNA Repair 2002, 1027-1038 (Pubitemid 35335828)
7. Kelner, M. J.; McMorris, T. C.; Taetle, R. Preclinical evaluation of illudins as anticancer agents: Basis for selective cytotoxicity J. Natl. Cancer Inst. 1990, 82, 1562-1656
8. Schobert, R.; Knauer, S.; Seibt, S.; Biersack, B. Anticancer active illudins: Recent developments of a potent alkylating compound class Curr. Med. Chem. 2011, 18, 790-807
9. Senzer, N.; Arsenau, J.; Richards, D.; Berman, B.; MacDonald, J. R.; Smith, S. Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial Am. J. Clin. Oncol. 2005, 28, 36-42 (Pubitemid 40209322)
10. Fouda, M. F. R.; Abd-Elzaher, M. M.; Abdelsamaia, R. A.; Labib, A. A. On the medicinal chemistry of ferrocene Appl. Organomet. Chem. 2007, 21, 613-625 (Pubitemid 47122081)
11. Gasser, G.; Ott, I.; Metzler-Nolte, N. Organometallic anticancer compounds J. Med. Chem. 2011, 54, 3-25
12. Kovjazin, R.; Eldar, T.; Patya, M.; Vanichkin, A.; Lander, H. M.; Novogrodsky, A. Ferrocene-induced lymphocyte activation and antitumor activity is mediated by redox-sensitive signaling FASEB J. 2003, 17, 467-469
13. Top, S.; Vessières, A.; Leclercq, G.; Quivy, J.; Tang, J.; Vaissermann, J.; Huché, M.; Jaouen, G. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines Chem.-Eur. J. 2003, 9, 5223-5236
14. Knauer, S.; Biersack, B.; Zoldakova, M.; Effenberger, K.; Milius, W.; Schobert, R. Melanoma-specific ferrocene esters of the fungal cytotoxin illudin M Anti-Cancer Drugs 2009, 20, 676-681
15. Rausch, M. D.; Fischer, E. O.; Grubert, H. The aromatic reactivity of ferrocene, ruthenocene and osmocene J. Am. Chem. Soc. 1960, 82, 76-82
16. Bestmann, H.-J.; Sandmeier, D. Eine neue Synthese des (Triphenylphosphoranyliden)ketens, seines Thioanalogen und stabiler Propadienylidentriphenylphosphorane Chem. Ber. 1980, 113, 274-277
17. Schobert, R.; Gordon, G.; Mullen, G.; Stehle, R. Microwave-accelerated Claisen rearrangements of allyl tetronates and tetramates Tetrahedron Lett. 2004, 45, 1121-1124 (Pubitemid 38165307)
18. Poindessous, V.; Koeppel, F.; Raymond, E.; Comisso, M.; Waters, S. J.; Larsen, A. K. Marked activity of irofulven toward human carcinoma cells: Comparison with cisplatin and ecteinascidin Clin. Cancer Res. 2003, 9, 2817-2825 (Pubitemid 36842128)
19. Wang, W.; Waters, S. J.; MacDonald, J. R.; Roth, C.; Shentu, S.; Freeman, J.; Von Hoff, D. D.; Miller, A. D. Irofulven (6-hydroxymethylacylfulvene, MGI-114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases Anticancer Res. 2002, 22, 559-564 (Pubitemid 34475201)
20. Petterson, F.; Couture, M.-C.; Hanna, N.; Milller, W. H., Jr. Enhanced retinoid-induced apoptosis of MDA-MB-231 breast cancer cells by PKC inhibitors involves activation of ERK Oncogene 2004, 23, 7053-7066 (Pubitemid 39319167)
21. Levina, A.; Mitra, A.; Lay, P. A. Recent developments in ruthenium anticancer drugs Metallomics 2009, 1, 458-470
22. Lipponer, K. G.; Vogel, E.; Keppler, B. K. Synthesis, characterization and solution chemistry of indazolium trans -tetrachlorobis(indazole) ruthenate(III), a new anticancer ruthenium complex. IR, UV, NMR, HPLC investigations and antitumor activity. Crystal structures of 1-methylindazolium trans -tetrachlorobis-(1-methyl-indazole)ruthenate(III) and its hydrolysis product trans -monoaqua-trichlorobis(1-methylindazole)ruthenate(III) Metal-Based Drugs 1996, 3, 243-260
23. Scolaro, C.; Bergamo, A.; Brescacin, L.; Delfino, R.; Cocchietto, M.; Laurenczy, G.; Geldbach, T. J.; Sava, G.; Dyson, P. J. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes J. Med. Chem. 2005, 48, 4161-4171 (Pubitemid 40803517)
24. Schobert, R.; Biersack, B.; Knauer, S.; Ocker, M. Conjugates of the fungal cytotoxin illudin M with improved tumour specificity Bioorg. Med. Chem. 2008, 16, 8592-8597
25. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 1983, 65, 55-63 (Pubitemid 14203433)
26. Ahmad, A.; Banerjee, S.; Wang, Z.; Kong, D.; Sarkar, F. H. Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-kappaB and Bcl-2 J. Cell. Biochem. 2008, 105, 1461-1471